Prosensa Holding BV (RNA)

[TheFinalCD]

Why Sarepta Therapeutics, Rentrak, and Prosensa Are Today's 3 Best Stocks

By Sean Williams
January 16, 2014
http://www.fool.com/investing/general/2014/01/16/why-sarepta-therapeutics-rentrak-and-prosensa-are.aspx




Finally, skipping from one Duchenne muscular dystrophy (DMD) rival to the next, Prosensa (NASDAQ: RNA ) advanced 24.4% after also presenting at the JPMorgan Healthcare Conference, and issuing a press release outlining additional clinical studies of drisapersen, its DMD drug, which failed miserably in late-stage studies in September. According to Prosensa, after further review of its clinical studies, it believes that earlier treatment of the disease, and therefore a longer period of treatment, could delay disease progression. Furthermore, Prosensa intends to consult with clinical experts and regulators to determine the next move for drisapersen. As I stated earlier today, I wouldn't get too excited about these initial findings, with the experimental drug delivering such unimpressive results in its phase 3 study. In addition, Prosensa no longer has a partner -- GlaxoSmithKline ended its pact with the company earlier this week...